Cardiokine Inc. is a specialty pharmaceutical company focused on the development of pharmaceuticals for the treatment and prevention of heart failure and related cardiovascular indications.

We both in-license and develop innovative new compounds and therapies to address what is a growing epidemic around the industrialized world. In the U.S. alone there are five million heart failure patients with over one million hospitalizations and 550,000 new cases each year. It is estimated that heart failure accounts for three billion dollars in pharmaceutical costs and $30 billion in total healthcare costs annually.